Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer.

Morotti M, Bridges E, Valli A, Choudhry H, Sheldon H, Wigfield S, Gray N, Zois CE, Grimm F, Jones D, Teoh EJ, Cheng WC, Lord S, Anastasiou D, Haider S, McIntyre A, Goberdhan DCI, Buffa F, Harris AL.

Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12452-12461. doi: 10.1073/pnas.1818521116. Epub 2019 May 31.

2.

Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer.

Yang J, AlTahan A, Jones DT, Buffa FM, Bridges E, Interiano RB, Qu C, Vogt N, Li JL, Baban D, Ragoussis J, Nicholson R, Davidoff AM, Harris AL.

Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15172-7. doi: 10.1073/pnas.1422015112. Epub 2015 Nov 23.

3.

Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.

Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S, Brodie AH.

Breast Cancer Res. 2014 Jan 29;16(1):R15. doi: 10.1186/bcr3609.

4.

Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.

Jia X, Hong Q, Lei L, Li D, Li J, Mo M, Wang Y, Shao Z, Shen Z, Cheng J, Liu G.

Oncotarget. 2015 Apr 20;6(11):8648-62.

5.
6.

Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.

Padró M, Louie RJ, Lananna BV, Krieg AJ, Timmerman LA, Chan DA.

BMC Cancer. 2017 Mar 20;17(1):203. doi: 10.1186/s12885-017-3140-9.

7.

Effects of Sodium and Amino Acid Substrate Availability upon the Expression and Stability of the SNAT2 (SLC38A2) Amino Acid Transporter.

Hoffmann TM, Cwiklinski E, Shah DS, Stretton C, Hyde R, Taylor PM, Hundal HS.

Front Pharmacol. 2018 Feb 7;9:63. doi: 10.3389/fphar.2018.00063. eCollection 2018.

8.

Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.

Long X, Fan M, Bigsby RM, Nephew KP.

Mol Cancer Ther. 2008 Jul;7(7):2096-108. doi: 10.1158/1535-7163.MCT-07-2350.

9.

HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells.

Alam MW, Persson CU, Reinbothe S, Kazi JU, Rönnstrand L, Wigerup C, Ditzel HJ, Lykkesfeldt AE, Påhlman S, Jögi A.

Oncotarget. 2016 Mar 8;7(10):11238-50. doi: 10.18632/oncotarget.7167.

10.

Estrogen-dependent downregulation of hypoxia-inducible factor (HIF)-2α in invasive breast cancer cells.

Fuady JH, Gutsche K, Santambrogio S, Varga Z, Hoogewijs D, Wenger RH.

Oncotarget. 2016 May 24;7(21):31153-65. doi: 10.18632/oncotarget.8866. Erratum in: Oncotarget. 2017 Mar 21;8(12 ):20516.

12.

Hypoxia reduces hormone responsiveness of human breast cancer cells.

Kurebayashi J, Otsuki T, Moriya T, Sonoo H.

Jpn J Cancer Res. 2001 Oct;92(10):1093-101.

13.

Hypoxia-inducible factor-1α (HIF-1α) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions.

Yi T, Papadopoulos E, Hagner PR, Wagner G.

J Biol Chem. 2013 Jun 28;288(26):18732-42. doi: 10.1074/jbc.M113.471466. Epub 2013 May 10.

14.

MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.

Bobustuc GC, Smith JS, Maddipatla S, Jeudy S, Limaye A, Isley B, Caparas ML, Constantino SM, Shah N, Baker CH, Srivenugopal KS, Baidas S, Konduri SD.

Mol Med. 2012 Sep 7;18:913-29. doi: 10.2119/molmed.2012.00010. Erratum in: Mol Med. 2012;18: doi/10.2119/molmed.2012.00006.erratum.

16.

Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.

Basak P, Chatterjee S, Bhat V, Su A, Jin H, Lee-Wing V, Liu Q, Hu P, Murphy LC, Raouf A.

Cell Physiol Biochem. 2018;51(4):1518-1532. doi: 10.1159/000495643. Epub 2018 Nov 29.

17.

HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs).

De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A, Maggiolini M.

Breast Cancer Res. 2013;15(4):R64.

18.

Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy.

Koda M, Kanczuga-Koda L, Sulkowska M, Surmacz E, Sulkowski S.

BMC Cancer. 2010 Jun 22;10:320. doi: 10.1186/1471-2407-10-320.

19.

Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.

Han Y, Yang L, Suarez-Saiz F, San-Marina S, Cui J, Minden MD.

Mol Cancer Res. 2008 Aug;6(8):1347-55. doi: 10.1158/1541-7786.MCR-07-2179.

Supplemental Content

Support Center